Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Import Program Would Need Funds To Inspect All U.S. Pharmacies, Agency Maintains

This article was originally published in The Pink Sheet Daily

Executive Summary

The pharmacy industry has told FDA all U.S. pharmacies will need to participate in a drug importation program to stay in business, so up to 55,000 pharmacies would have to be inspected, FDA's McGinnis says. "Draconian" penalties for non-complying drug manufacturers would ensure ample flow of drugs from Canada, he says.

You may also be interested in...



AARP Will Continue To Support Dorgan/Snowe Drug Import Bill In 2005

The organization maintains that the Dorgan bill addresses the safety concerns contained in the HHS Importation Task Force report. AARP’s legislative agenda includes supporting proposals to make Medicaid more efficient and expanding its Medicare Rx awareness campaign.

AARP Will Continue To Support Dorgan/Snowe Drug Import Bill In 2005

The organization maintains that the Dorgan bill addresses the safety concerns contained in the HHS Importation Task Force report. AARP’s legislative agenda includes supporting proposals to make Medicaid more efficient and expanding its Medicare Rx awareness campaign.

Rx Import Bills Do Not Have Adequate Funding For FDA, Agency Says

Senate bills "do not go far enough" in allowing FDA to assure safety and efficacy of imported drugs, FDA's Hubbard tells Judiciary Committee hearing. Senate Health Committee will mark up Sen. Gregg's import bill July 21.

Related Content

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel